The US Food and Drug Administration today approved Perjeta (pertuzumab), a new intravenously-administered therapy against HER2-positive late-stage breast cancer.
Perjeta is intended for patients who have not received prior treatment for metastatic breast cancer with an anti-HER2 therapy or chemotherapy, and is combined with trastuzumab, another anti-HER2 therapy, and docetaxel, a type of chemotherapy.
To read the full FDA brief and for more information, click here.
